Literature DB >> 3351693

Furosemide pharmacokinetics in very low birth weight infants.

M H Mirochnick1, J J Miceli, P A Kramer, D J Chapron, J R Raye.   

Abstract

The pharmacokinetics of furosemide were studied longitudinally during long-term administration in 10 very low birth weight infants with bronchopulmonary dysplasia. Mean birth weight of the infants was 829 +/- 217 g, mean gestational age at birth was 26.6 +/- 2.9 weeks, and mean postnatal age at the start of therapy was 2.4 +/- 1.0 weeks. Serial determinations of furosemide pharmacokinetic parameters were performed during 2 weeks to 3 months of long-term therapy. Plasma half-life was prolonged in infants less than 31 weeks postconceptional age (gestational + postnatal age), frequently exceeding 24 hours. All infants less than 29 weeks postconceptional age whose dosing schedule was once every 12 hours accumulated furosemide to potentially ototoxic levels. Furosemide renal clearance increased and plasma half-life decreased in association with increasing postconceptional age. Furosemide secretory clearance was very low in patients less than 31 weeks postconceptional age, resulting in a reliance on glomerular filtration to deliver drug to its main site of action within the lumen of the loop of Henle. Thus elevated plasma levels may be required to ensure adequate luminal delivery and adequate diuresis in these infants with low secretory clearance. Nevertheless, the current dosing schedule (once every 12 hours) of furosemide should be modified to once every 24 hours in infants of low postconceptional age to avoid possible toxic effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3351693     DOI: 10.1016/s0022-3476(88)80192-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Management of fluid balance in the very immature neonate.

Authors:  N Modi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

Review 2.  Diuretics in pediatrics : current knowledge and future prospects.

Authors:  Maria M J van der Vorst; Joana E Kist; Albert J van der Heijden; Jacobus Burggraaf
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.

Authors:  Audra Stewart; Luc P Brion
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

Review 4.  Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships.

Authors:  D A Sica; T W Gehr
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

5.  Nebulized furosemide in the treatment of bronchopulmonary dysplasia in preterm infants.

Authors:  Jasmine Sahni; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

Review 6.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 7.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

8.  Development, validation, and implementation of an UHPLC-MS/MS method for the quantitation of furosemide in infant urine samples.

Authors:  Christina Vedar; Nicolas A Bamat; Athena F Zuppa; Megan E Reilly; Ganesh S Moorthy
Journal:  Biomed Chromatogr       Date:  2021-11-28       Impact factor: 1.902

Review 9.  The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants.

Authors:  Sarah Dudley; Shawn Sen; Alison Hanson; Afif El Khuffash; Philip T Levy
Journal:  J Perinatol       Date:  2022-07-15       Impact factor: 3.225

Review 10.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.